AbbVie Inc. (ABBV) Free Cash Flow Yield: 5.23%
Is AbbVie Inc.’s free cash flow yield high or low?
AbbVie Inc.'s free cash flow yield of 5.23% is 29% below its 5-year average of 7.31%, near the low end of its 5-year range (4.21%–10.58%).
As of Friday, June 12, 2026. 5.58% above its 12-month average of 4.95%.
ABBV Free Cash Flow Yield Chart
ABBV Average Free Cash Flow Yield Chart
ABBV Current vs Average Free Cash Flow Yield Chart
ABBV Free Cash Flow Yield Metrics
FREE CASH FLOW YIELD
5.23%
FREE CASH FLOW YIELD AVG TTM
4.95%
FREE CASH FLOW YIELD AVG 3Y
6.33%
FREE CASH FLOW YIELD AVG 5Y
7.31%
FREE CASH FLOW YIELD AVG 10Y
7.78%
FREE CASH FLOW YIELD AVG 15Y
7.39%
FREE CASH FLOW YIELD AVG 20Y
7.39%
CURRENT VS TTM AVG
+5.58%
CURRENT VS 3Y AVG
-17.39%
CURRENT VS 5Y AVG
-28.50%
CURRENT VS 10Y AVG
-32.75%
CURRENT VS 15Y AVG
-29.25%
CURRENT VS 20Y AVG
-29.25%
ABBV Competitors' Free Cash Flow Yield
| NAME | MARKET CAP | FREE CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| AbbVie Inc. (ABBV) | $397.12B | 5.23% | 4.95% | 6.33% | 7.31% |
| UnitedHealth Group Incorporated (UNH) | $368.30B | 5.33% | 7.01% | 5.44% | 5.29% |
| Merck & Co., Inc. (MRK) | $298.29B | 4.73% | 5.83% | 5.24% | 5.04% |
| AstraZeneca PLC (AZN) | $282.69B | 3.20% | 3.67% | 3.35% | 3.11% |
| Johnson & Johnson (JNJ) | $573.71B | 3.05% | 3.75% | 4.32% | 4.36% |
| Amgen Inc. (AMGN) | $191.09B | 4.46% | 5.89% | 5.48% | 5.88% |
| Thermo Fisher Scientific Inc. (TMO) | $176.77B | 3.80% | 3.34% | 3.39% | 3.32% |
| Gilead Sciences, Inc. (GILD) | $156.28B | 6.48% | 6.07% | 7.45% | 8.69% |
| Abbott Laboratories (ABT) | $156.15B | 4.71% | 3.47% | 3.07% | 3.51% |
| Pfizer Inc. (PFE) | $149.18B | 6.33% | 7.35% | 5.93% | 7.34% |
Yield Comparison
FCF Yield
5.23%
Earnings Yield
0.91%
Dividend Yield
3.00%
Formula: FCF Yield = (Free Cash Flow / Market Cap) × 100
How FCF Yield is used:
- Shows free cash flow after capital expenditures relative to market cap
- Can be compared with earnings yield and dividend yield
- Can be compared with the company's historical range
- Can be compared with peers that report positive free cash flow
FCF vs earnings: Differences between FCF yield and earnings yield can reflect capital expenditures, working capital changes, and other non-cash accounting items.
AbbVie Inc. Free Cash Flow Yield Formula & Definition
FCF Yield measures free cash flow relative to market capitalization. It compares cash generation after capital expenditures with the equity value of the company.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
AbbVie Inc. Free Cash Flow Yield FAQ
- What is the free cash flow yield for AbbVie Inc. (ABBV)?
- The free cash flow yield for ABBV stock is 5.23%.
- Is AbbVie Inc.'s free cash flow yield high or low?
- AbbVie Inc.'s free cash flow yield of 5.23% is 29% below its 5-year average of 7.31%, near the low end of its 5-year range (4.21%–10.58%).
- What is the TTM average free cash flow yield for AbbVie Inc. (ABBV)?
- The TTM average free cash flow yield for ABBV stock is 4.95%.
- What is the 3Y average free cash flow yield for AbbVie Inc. (ABBV)?
- The 3Y average free cash flow yield for ABBV stock is 6.33%.
- What is the 5Y average free cash flow yield for AbbVie Inc. (ABBV)?
- The 5Y average free cash flow yield for ABBV stock is 7.31%.
- What is the 10Y average free cash flow yield for AbbVie Inc. (ABBV)?
- The 10Y average free cash flow yield for ABBV stock is 7.78%.
- What is the 15Y average free cash flow yield for AbbVie Inc. (ABBV)?
- The 15Y average free cash flow yield for ABBV stock is 7.39%.
- What is the 20Y average free cash flow yield for AbbVie Inc. (ABBV)?
- The 20Y average free cash flow yield for ABBV stock is 7.39%.
AbbVie Inc. Free Cash Flow Yield History
| DATE | FREE CASH FLOW YIELD |
|---|---|
| 2026-06-11 | 5.23% |
| 2026-06-10 | 5.23% |
| 2026-06-09 | 5.22% |
| 2026-06-08 | 5.27% |
| 2026-06-05 | 5.18% |
| 2026-06-04 | 5.23% |
| 2026-06-03 | 5.42% |
| 2026-06-02 | 5.46% |
| 2026-06-01 | 5.52% |
| 2026-05-29 | 5.40% |
| 2026-05-28 | 5.38% |
| 2026-05-27 | 5.46% |
| 2026-05-26 | 5.52% |
| 2026-05-22 | 5.45% |
| 2026-05-21 | 5.48% |
| 2026-05-20 | 5.54% |
| 2026-05-19 | 5.50% |
| 2026-05-18 | 5.62% |
| 2026-05-15 | 5.59% |
| 2026-05-14 | 5.58% |
| 2026-05-13 | 5.64% |
| 2026-05-12 | 5.66% |
| 2026-05-11 | 5.80% |
| 2026-05-08 | 5.83% |
| 2026-05-07 | 5.20% |
| 2026-05-06 | 5.14% |
| 2026-05-05 | 5.12% |
| 2026-05-04 | 5.06% |
| 2026-05-01 | 5.10% |
| 2026-04-30 | 4.99% |
| 2026-04-29 | 5.17% |
| 2026-04-28 | 5.33% |
| 2026-04-27 | 5.34% |
| 2026-04-24 | 5.31% |
| 2026-04-23 | 5.25% |
| 2026-04-22 | 5.26% |
| 2026-04-21 | 5.14% |
| 2026-04-20 | 5.18% |
| 2026-04-17 | 5.06% |
| 2026-04-16 | 5.04% |
| 2026-04-15 | 5.06% |
| 2026-04-14 | 5.01% |
| 2026-04-13 | 5.10% |
| 2026-04-10 | 5.07% |
| 2026-04-09 | 4.96% |
| 2026-04-08 | 4.98% |
| 2026-04-07 | 5.11% |
| 2026-04-06 | 5.10% |
| 2026-04-02 | 5.05% |
| 2026-04-01 | 4.90% |
| 2026-03-31 | 4.85% |
| 2026-03-30 | 4.95% |
| 2026-03-27 | 5.04% |
| 2026-03-26 | 4.99% |
| 2026-03-25 | 5.09% |
| 2026-03-24 | 5.14% |
| 2026-03-23 | 5.14% |
| 2026-03-20 | 5.14% |
| 2026-03-19 | 5.11% |
| 2026-03-18 | 5.06% |
| 2026-03-17 | 4.80% |
| 2026-03-16 | 4.76% |
| 2026-03-13 | 4.80% |
| 2026-03-12 | 4.68% |
| 2026-03-11 | 4.63% |
| 2026-03-10 | 4.64% |
| 2026-03-09 | 4.63% |
| 2026-03-06 | 4.58% |
| 2026-03-05 | 4.54% |
| 2026-03-04 | 4.46% |
| 2026-03-03 | 4.51% |
| 2026-03-02 | 4.50% |
| 2026-02-27 | 4.54% |
| 2026-02-26 | 4.69% |
| 2026-02-25 | 4.64% |
| 2026-02-24 | 4.61% |
| 2026-02-23 | 4.59% |
| 2026-02-20 | 4.69% |
| 2026-02-19 | 5.17% |
| 2026-02-18 | 5.08% |
| 2026-02-17 | 4.99% |
| 2026-02-13 | 5.02% |
| 2026-02-12 | 5.10% |
| 2026-02-11 | 5.26% |
| 2026-02-10 | 5.22% |
| 2026-02-09 | 5.20% |
| 2026-02-06 | 5.19% |
| 2026-02-05 | 5.30% |
| 2026-02-04 | 5.35% |
| 2026-02-03 | 5.14% |
| 2026-02-02 | 5.14% |
| 2026-01-30 | 5.21% |
| 2026-01-29 | 5.27% |
| 2026-01-28 | 5.31% |
| 2026-01-27 | 5.18% |
| 2026-01-26 | 5.26% |
| 2026-01-23 | 5.29% |
| 2026-01-22 | 5.32% |
| 2026-01-21 | 5.37% |
| 2026-01-20 | 5.42% |
| 2026-01-16 | 5.41% |
| 2026-01-15 | 5.36% |
| 2026-01-14 | 5.23% |
| 2026-01-13 | 5.26% |
| 2026-01-12 | 5.27% |
| 2026-01-09 | 5.27% |
| 2026-01-08 | 5.18% |
| 2026-01-07 | 4.97% |
| 2026-01-06 | 5.18% |
| 2026-01-05 | 5.27% |
| 2026-01-02 | 5.06% |
| 2025-12-31 | 5.08% |
| 2025-12-30 | 5.05% |
| 2025-12-29 | 5.03% |
| 2025-12-26 | 5.05% |
| 2025-12-24 | 5.05% |
| 2025-12-23 | 5.07% |
| 2025-12-22 | 5.09% |
| 2025-12-19 | 5.12% |
| 2025-12-18 | 5.21% |
| 2025-12-17 | 5.18% |
| 2025-12-16 | 5.19% |
| 2025-12-15 | 5.10% |
| 2025-12-12 | 5.20% |
| 2025-12-11 | 5.18% |
| 2025-12-10 | 5.15% |
| 2025-12-09 | 5.21% |
| 2025-12-08 | 5.20% |
| 2025-12-05 | 5.13% |
| 2025-12-04 | 5.08% |
| 2025-12-03 | 5.04% |
| 2025-12-02 | 5.17% |
| 2025-12-01 | 5.16% |
| 2025-11-28 | 5.10% |
| 2025-11-26 | 5.10% |
| 2025-11-25 | 5.01% |
| 2025-11-24 | 5.06% |
| 2025-11-21 | 4.91% |
| 2025-11-20 | 5.06% |
| 2025-11-19 | 4.99% |
| 2025-11-18 | 4.96% |
| 2025-11-17 | 4.96% |
| 2025-11-14 | 5.00% |
| 2025-11-13 | 5.00% |
| 2025-11-12 | 4.98% |
| 2025-11-11 | 5.15% |
| 2025-11-10 | 5.31% |
| 2025-11-07 | 5.30% |
| 2025-11-06 | 5.30% |
| 2025-11-05 | 5.36% |
| 2025-11-04 | 5.38% |
| 2025-11-03 | 4.86% |
| 2025-10-31 | 4.72% |
| 2025-10-30 | 4.51% |
| 2025-10-29 | 4.57% |
| 2025-10-28 | 4.52% |
| 2025-10-27 | 4.51% |
| 2025-10-24 | 4.51% |
| 2025-10-23 | 4.51% |
| 2025-10-22 | 4.50% |
| 2025-10-21 | 4.45% |
| 2025-10-20 | 4.43% |
| 2025-10-17 | 4.48% |
| 2025-10-16 | 4.54% |
| 2025-10-15 | 4.55% |
| 2025-10-14 | 4.49% |
| 2025-10-13 | 4.47% |
| 2025-10-10 | 4.47% |
| 2025-10-09 | 4.46% |
| 2025-10-08 | 4.45% |
| 2025-10-07 | 4.42% |
| 2025-10-06 | 4.47% |
| 2025-10-03 | 4.40% |
| 2025-10-02 | 4.35% |
| 2025-10-01 | 4.21% |
| 2025-09-30 | 4.44% |
| 2025-09-29 | 4.61% |
| 2025-09-26 | 4.67% |
| 2025-09-25 | 4.71% |
| 2025-09-24 | 4.68% |
| 2025-09-23 | 4.62% |
| 2025-09-22 | 4.62% |
| 2025-09-19 | 4.63% |
| 2025-09-18 | 4.64% |
| 2025-09-17 | 4.66% |
| 2025-09-16 | 4.76% |
| 2025-09-15 | 4.73% |
| 2025-09-12 | 4.71% |
| 2025-09-11 | 4.67% |
| 2025-09-10 | 4.86% |
| 2025-09-09 | 4.89% |
| 2025-09-08 | 4.91% |
| 2025-09-05 | 4.84% |
| 2025-09-04 | 4.83% |
| 2025-09-03 | 4.86% |
| 2025-09-02 | 4.86% |
| 2025-08-29 | 4.89% |
| 2025-08-28 | 4.95% |
| 2025-08-27 | 4.95% |
| 2025-08-26 | 4.94% |
| 2025-08-25 | 4.96% |
| 2025-08-22 | 4.89% |
| 2025-08-21 | 4.91% |
| 2025-08-20 | 4.92% |
| 2025-08-19 | 4.99% |
| 2025-08-18 | 4.98% |
| 2025-08-15 | 4.98% |
| 2025-08-14 | 5.03% |
| 2025-08-13 | 5.11% |
| 2025-08-12 | 5.18% |
| 2025-08-11 | 5.18% |
| 2025-08-08 | 5.20% |
| 2025-08-07 | 5.18% |
| 2025-08-06 | 5.24% |
| 2025-08-05 | 5.18% |
| 2025-08-04 | 5.22% |
| 2025-08-01 | 4.45% |
| 2025-07-31 | 4.59% |
| 2025-07-30 | 4.59% |
| 2025-07-29 | 4.54% |
| 2025-07-28 | 4.61% |
| 2025-07-25 | 4.56% |
| 2025-07-24 | 4.55% |
| 2025-07-23 | 4.56% |
| 2025-07-22 | 4.64% |
| 2025-07-21 | 4.70% |
| 2025-07-18 | 4.59% |
| 2025-07-17 | 4.54% |
| 2025-07-16 | 4.56% |
| 2025-07-15 | 4.66% |
| 2025-07-14 | 4.53% |
| 2025-07-11 | 4.51% |
| 2025-07-10 | 4.45% |
| 2025-07-09 | 4.55% |
| 2025-07-08 | 4.57% |
| 2025-07-07 | 4.63% |
| 2025-07-03 | 4.59% |
| 2025-07-02 | 4.55% |
| 2025-07-01 | 4.57% |
| 2025-06-30 | 4.68% |
| 2025-06-27 | 4.76% |
| 2025-06-26 | 4.65% |
| 2025-06-25 | 4.68% |
| 2025-06-24 | 4.68% |
| 2025-06-23 | 4.73% |
| 2025-06-20 | 4.69% |
| 2025-06-18 | 4.68% |
| 2025-06-17 | 4.68% |
| 2025-06-16 | 4.55% |
| 2025-06-13 | 4.54% |
| 2025-06-12 | 4.51% |
| 2025-06-11 | 4.53% |
| 2025-06-10 | 4.58% |
| 2025-06-09 | 4.59% |
| 2025-06-06 | 4.57% |
| 2025-06-05 | 4.63% |
| 2025-06-04 | 4.63% |
| 2025-06-03 | 4.64% |
| 2025-06-02 | 4.64% |
| 2025-05-30 | 4.66% |
Showing the most recent 260 of 3,396 data points. The chart above shows the full history.
About AbbVie Inc.
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert A. Michael